Nissim Darvish - Jun 14, 2023 Form 4 Insider Report for Chemomab Therapeutics Ltd. (CMMB)

Role
Director
Signature
/s/ Matthew Rudolph, Esq., Attorney-in-Fact for Nissim Darvish
Stock symbol
CMMB
Transactions as of
Jun 14, 2023
Transactions value $
$0
Form type
4
Date filed
7/5/2023, 05:48 PM
Previous filing
Mar 23, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding CMMB American Depositary Shares 1.2K Jun 14, 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CMMB Option to Purchase American Depositary Shares Award $0 +20.6K $0.00 20.6K Jun 14, 2023 American Depositary Shares 20.6K $1.70 Direct F1, F2, F3
transaction CMMB Option to Purchase American Depositary Shares Award $0 +6.86K $0.00 6.86K Mar 16, 2023 American Depositary Shares 6.86K $1.62 Direct F1, F2, F4
transaction CMMB Option to Purchase American Depositary Shares Award $0 +6.82K $0.00 6.82K Mar 7, 2022 American Depositary Shares 6.82K $3.53 Direct F1, F2, F5
transaction CMMB Option to Purchase American Depositary Shares Award $0 +11.9K $0.00 11.9K Apr 19, 2021 American Depositary Shares 11.9K $27.26 Direct F1, F2, F6
transaction CMMB Option to Purchase American Depositary Shares Award $0 +10.1K $0.00 10.1K Oct 28, 2016 American Depositary Shares 10.1K $0.80 Direct F1, F2, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only.
F2 Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.
F3 These options vest and become exercisable in equal monthly installments over a 36 month period, subject to the Reporting Person's continued service.
F4 These options were granted as per the annual grant of options to directors. These options vest and become exercisable in their entirety on March 16, 2024, subject to the Reporting Person's continued service.
F5 These options vested and became exercisable in their entirety on March 16, 2023. These options were granted as per the annual grant of options to directors.
F6 These options vest and become exercisable in equal monthly installments over a 36 month period commencing on March 16, 2021, subject to the Reporting Person's continued service.
F7 The options reported in this row have all vested and are exercisable as of the date hereof, subject to the Reporting Person's continued service.